Patents by Inventor Christophe Blanchetot
Christophe Blanchetot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109960Abstract: The instant disclosure provides isolated antibodies that specifically bind to IL-9 (e.g., human IL-9 or mouse IL-9). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: December 14, 2023Publication date: April 4, 2024Inventors: Christophe BLANCHETOT, Marie GODAR
-
Publication number: 20240034779Abstract: Antibodies that specifically bind to complement factor D in a pH sensitive manner, are described, as well as methods of making and using such antibodies.Type: ApplicationFiled: October 6, 2023Publication date: February 1, 2024Inventors: Sebastien Vallee, Madhusudan Natarajan, Rizwana Islam, Muthuraman Meiyappan, Angela Norton, Niksa Kastrapeli, Christophe Blanchetot, Christophe Steyaert
-
Publication number: 20240026010Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: ApplicationFiled: June 7, 2023Publication date: January 25, 2024Inventors: Jean-Michel PERCIER, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
-
Publication number: 20240002484Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: ApplicationFiled: June 7, 2023Publication date: January 4, 2024Inventors: Christophe BLANCHETOT, Hans DE HAARD
-
Patent number: 11827701Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: GrantFiled: August 10, 2021Date of Patent: November 28, 2023Assignee: ARGENX BVInventors: Christophe Blanchetot, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Natalie De Jonge, Sebastian Paul Van Der Woning, Nicolas Ongenae
-
Patent number: 11713354Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: GrantFiled: March 8, 2021Date of Patent: August 1, 2023Assignees: ARGENX BV, VIB VZW, Universiteit GentInventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
-
Patent number: 11708403Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: GrantFiled: January 10, 2022Date of Patent: July 25, 2023Assignee: ARGENX BVInventors: Christophe Blanchetot, Hans De Haard
-
Publication number: 20230151091Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.Type: ApplicationFiled: October 3, 2022Publication date: May 18, 2023Inventors: Steven J. BURDEN, Shohei KOIDE, Akiko KOIDE, Nadia LELOUP, Julien OURY, Karen SILENCE, Roeland VANHAUWAERT, Christophe BLANCHETOT
-
Publication number: 20230110188Abstract: The present invention relates to a MuSK agonist antibody, or a VH, VL or CDR3 thereof, a polynucleotide encoding said antibody or a VH, VL or CDR3 thereof or an expression vector comprising said polynucleotide or a composition comprising said antibody, polynucleotide or expression vector and their use in methods of preventing and treating diseases and conditions associated with an impaired neuromuscular transmission.Type: ApplicationFiled: September 9, 2022Publication date: April 13, 2023Inventors: Christophe BLANCHETOT, Christophe STEYAERT, Dana VERGOOSSEN, Jakob Jan PLOMP, Kasra SAMAREH TALEBI, Johannes Justus Gerard Maria VERSCHUUREN, Silvère Maria VAN DER MAAREL, Martina Gerardina Maria HUIJBERS
-
Patent number: 11591386Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: GrantFiled: October 1, 2021Date of Patent: February 28, 2023Assignee: argenx BVInventors: Christophe Blanchetot, Hans De Haard
-
Patent number: 11505585Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: November 22, 2017Date of Patent: November 22, 2022Assignees: argenx BV, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 11492401Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.Type: GrantFiled: December 30, 2021Date of Patent: November 8, 2022Assignees: NEW YORK UNIVERSITY, ARGENX IIP BVInventors: Steven J. Burden, Shohei Koide, Akiko Koide, Nadia Leloup, Julien Oury, Karen Silence, Roeland Vanhauwaert, Christophe Blanchetot
-
Publication number: 20220275035Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: February 15, 2022Publication date: September 1, 2022Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20220267424Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: ApplicationFiled: January 10, 2022Publication date: August 25, 2022Inventors: Christophe Blanchetot, Hans de Haard
-
Publication number: 20220259304Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.Type: ApplicationFiled: December 30, 2021Publication date: August 18, 2022Inventors: Steven J. BURDEN, Shohei KOIDE, Akiko KOIDE, Nadia LELOUP, Julien OURY, Karen SILENCE, Roeland VANHAUWAERT, Christophe BLANCHETOT
-
Publication number: 20220177555Abstract: Methods for preparing engineered antibodies exhibiting improved pH-dependent antigen binding are disclosed. The methods are based on introduction of histidine residues at a subset of defined amino acid positions within the antibody CDRs. The set of amino acid positions selected for histidine substitution is derived from a heat-map of histidine occurrence within the CDRs of functional antibodies from a natural antibody repertoire. The methods provide a simpler and less time-consuming approach to the identification of pH-dependent antibody variants.Type: ApplicationFiled: May 10, 2018Publication date: June 9, 2022Inventors: Christophe BLANCHETOT, Erik HOFMAN, Johannes DE HAARD, Jacobus Cornelis RASSER
-
Publication number: 20220177604Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.Type: ApplicationFiled: April 9, 2020Publication date: June 9, 2022Inventors: Michael SAUNDERS, Rene BIGIRIMANA, Christophe BLANCHETOT, Marijn CROMHEECKE, Conor MCGUIRE
-
Publication number: 20220119509Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: ApplicationFiled: October 1, 2021Publication date: April 21, 2022Inventors: Christophe BLANCHETOT, Hans DE HAARD
-
Publication number: 20220073604Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: ApplicationFiled: August 10, 2021Publication date: March 10, 2022Inventors: Christophe BLANCHETOT, Johannes DE HAARD, Torsten DREIER, Natalie DE JONGE, Sebastian Paul VAN DER WONING, Nicolas ONGENAE
-
Patent number: 11161900Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: GrantFiled: December 13, 2019Date of Patent: November 2, 2021Assignee: argenx BVBAInventors: Christophe Blanchetot, Hans de Haard